BioCryst cuts 2026 non-GAAP operating expense outlook to $420 million-$440 million

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

BCRX

0.00
  • BioCryst cut 2026 non-GAAP operating expense guidance to $420-$440 million from $450-$470 million.
  • Cost outlook reflects a shift to external innovation, a wind-down of internal discovery programs, closure of the Birmingham research facility by end-2026.
  • 2026 ORLADEYO revenue outlook maintained at $625-$645 million.
  • 2026 total revenue outlook unchanged at $635-$660 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290700PRIMZONEFULLFEED9753742) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.